Autolus Therapeutics (AUTL) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

AUTL Stock Forecast


Autolus Therapeutics stock forecast is as follows: an average price target of $9.50 (represents a 184.43% upside from AUTL’s last price of $3.34) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

AUTL Price Target


The average price target for Autolus Therapeutics (AUTL) is $9.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $8.00. This represents a potential 184.43% upside from AUTL's last price of $3.34.

AUTL Analyst Ratings


Buy

According to 3 Wall Street analysts, Autolus Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AUTL stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Autolus Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 20, 2024Yanan ZhuWells Fargo$8.00$4.3982.23%139.52%
Apr 08, 2024Asthika GoonewardeneTruist Financial$11.00$5.5398.92%229.34%
Mar 15, 2024Asthika GoonewardeneTruist Financial$10.00$5.8271.82%199.40%
Row per page
Go to

The latest Autolus Therapeutics stock forecast, released on May 20, 2024 by Yanan Zhu from Wells Fargo, set a price target of $8.00, which represents a 82.23% increase from the stock price at the time of the forecast ($4.39), and a 139.52% increase from AUTL last price ($3.34).

Autolus Therapeutics Price Target by Period


1M3M12M
# Anlaysts--3
Avg Price Target--$9.67
Last Closing Price$3.34$3.34$3.34
Upside/Downside-100.00%-100.00%189.52%

In the current month, the average price target of Autolus Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Autolus Therapeutics's last price of $3.34. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jun 17, 2024NeedhamBuyBuyHold
May 20, 2024Wells FargoOverweightOverweightHold
Mar 18, 2024NeedhamBuyBuyHold
Mar 08, 2023Piper SandlerBuyBuyHold
Dec 09, 2022NeedhamBuyBuyHold
Row per page
Go to

Autolus Therapeutics's last stock rating was published by Needham on Jun 17, 2024. The company gave AUTL a "Buy" rating, the same as its previous rate.

Autolus Therapeutics Financial Forecast


Autolus Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$406.00K-$1.29M$3.83M$2.37M--$823.00K-$1.51M$269.00K-$242.00K$293.00K$338.00K$309.00K$297.00K
Avg Forecast$44.28M$37.73M$26.38M$19.94M$20.10M$16.28M$12.88M$10.13M$168.75K$193.75K$93.75K$29.01M$358.40K$624.80K$136.50K$379.29K$11.18M$144.29K$240.56K$171.43K$6.58M$291.68K$212.15K$344.63K$293.89K$303.11K$327.00K$500.00K$450.00K$480.00K
High Forecast$44.28M$37.73M$26.38M$19.94M$20.10M$16.28M$12.88M$10.13M$168.75K$193.75K$93.88K$29.01M$358.40K$624.90K$136.50K$379.29K$11.18M$144.29K$240.56K$171.43K$6.58M$291.68K$212.15K$344.63K$293.89K$303.11K$327.00K$500.00K$450.00K$480.00K
Low Forecast$44.28M$37.73M$26.38M$19.94M$20.10M$16.28M$12.88M$10.13M$168.75K$193.75K$93.63K$29.01M$358.40K$624.70K$136.50K$379.29K$11.18M$144.29K$240.56K$171.43K$6.58M$291.68K$212.15K$344.63K$293.89K$303.11K$327.00K$500.00K$450.00K$480.00K
# Analysts11111111131131111111119151016811711
Surprise %-------------0.65%-3.41%0.34%16.42%--0.13%-7.10%0.78%-0.80%0.90%0.68%0.69%0.62%

Autolus Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $358.40K, with a low forecast of $358.40K, and a high forecast of $358.40K. AUTL's average Quarter revenue forecast represents a -11.72% decrease compared to the company's last Quarter revenue of $406.00K (Sep 23).

Autolus Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts11111111131131111111119151016811711
EBITDA------------$-40.89M$-44.01M$-42.47M$-33.21M$-26.45M$-45.28M$-45.80M$-38.83M$-45.50M$-37.91M$-35.48M$-36.87M$-45.67M$-41.24M$-38.28M$-37.30M$-37.69M$-34.48M
Avg Forecast$-44.28M$-37.73M$-26.38M$-19.94M$-20.10M$-16.28M$-12.88M$-10.13M$-168.75K$-193.75K$-93.75K$-61.91M$-358.40K$-624.80K$-136.50K$-56.28M$-25.62M$-144.29K$-240.56K$-44.49M$-6.58M$-291.68K$-212.15K$-41.68M$-293.89K$-303.11K$-327.00K$-38.42M$-450.00K$-480.00K
High Forecast$-44.28M$-37.73M$-26.38M$-19.94M$-20.10M$-16.28M$-12.88M$-10.13M$-168.75K$-193.75K$-93.63K$-49.53M$-358.40K$-624.70K$-136.50K$-45.03M$-20.50M$-144.29K$-240.56K$-35.59M$-6.58M$-291.68K$-212.15K$-33.35M$-293.89K$-303.11K$-327.00K$-30.74M$-450.00K$-480.00K
Low Forecast$-44.28M$-37.73M$-26.38M$-19.94M$-20.10M$-16.28M$-12.88M$-10.13M$-168.75K$-193.75K$-93.88K$-74.29M$-358.40K$-624.90K$-136.50K$-67.54M$-30.75M$-144.29K$-240.56K$-53.39M$-6.58M$-291.68K$-212.15K$-50.02M$-293.89K$-303.11K$-327.00K$-46.10M$-450.00K$-480.00K
Surprise %------------114.08%70.44%311.11%0.59%1.03%313.84%190.41%0.87%6.92%129.96%167.23%0.88%155.39%136.06%117.06%0.97%83.76%71.83%

undefined analysts predict AUTL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Autolus Therapeutics's previous annual EBITDA (undefined) of $NaN.

Autolus Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts11111111131131111111119151016811711
Net Income------------$-77.17M$-45.85M$-45.55M$-39.81M$-26.95M$-42.77M$-42.06M$-37.06M$-41.67M$-33.99M$-33.17M$-33.27M$-42.86M$-37.31M$-32.05M$-29.87M$-40.94M$-27.25M
Avg Forecast$-31.14M$-37.58M$-49.07M$-46.85M$-50.23M$-54.67M$-59.74M$-58.87M$-54.01M$-56.99M$-51.74M$-59.09M$-67.27M$-66.38M$-59.45M$-53.72M$-23.40M$-125.50M$-111.73M$-42.47M$-102.57M$-134.40M$-132.63M$-37.15M$-203.66M$-187.99M$-188.58M$-35.52M$-196.41M$-228.78M
High Forecast$-31.14M$-37.58M$-49.07M$-46.85M$-50.23M$-54.67M$-59.74M$-58.87M$-54.01M$-51.56M$-51.74M$-47.27M$-59.51M$-66.38M$-59.45M$-42.98M$-18.72M$-125.50M$-111.73M$-33.97M$-102.57M$-134.40M$-132.63M$-29.72M$-203.66M$-187.99M$-188.58M$-28.42M$-196.41M$-228.78M
Low Forecast$-31.14M$-37.58M$-49.07M$-46.85M$-50.23M$-54.67M$-59.74M$-58.87M$-54.01M$-59.70M$-51.74M$-70.91M$-75.04M$-66.38M$-59.45M$-64.46M$-28.08M$-125.50M$-111.73M$-50.96M$-102.57M$-134.40M$-132.63M$-44.58M$-203.66M$-187.99M$-188.58M$-42.63M$-196.41M$-228.78M
Surprise %------------1.15%0.69%0.77%0.74%1.15%0.34%0.38%0.87%0.41%0.25%0.25%0.90%0.21%0.20%0.17%0.84%0.21%0.12%

Autolus Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AUTL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Autolus Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts11111111131131111111119151016811711
SG&A------------$15.73M$10.61M$11.12M$9.28M$7.41M$8.23M$8.27M$7.99M$7.59M$8.30M$7.24M$8.74M$9.01M$9.84M$8.51M$7.61M$9.92M$8.61M
Avg Forecast$1.78B$1.51B$1.06B$799.82M$806.13M$652.89M$516.50M$406.41M$6.77M$7.77M$3.76M$12.73M$14.38M$25.06M$5.48M$15.21M$8.61M$5.79M$9.65M$6.88M$263.76M$11.70M$8.51M$13.82M$11.79M$12.16M$13.12M$20.06M$18.05M$19.25M
High Forecast$1.78B$1.51B$1.06B$799.82M$806.13M$652.89M$516.50M$406.41M$6.77M$7.77M$3.77M$15.28M$14.38M$25.07M$5.48M$15.21M$10.33M$5.79M$9.65M$6.88M$263.76M$11.70M$8.51M$13.82M$11.79M$12.16M$13.12M$20.06M$18.05M$19.25M
Low Forecast$1.78B$1.51B$1.06B$799.82M$806.13M$652.89M$516.50M$406.41M$6.77M$7.77M$3.76M$10.19M$14.38M$25.06M$5.48M$15.21M$6.88M$5.79M$9.65M$6.88M$263.76M$11.70M$8.51M$13.82M$11.79M$12.16M$13.12M$20.06M$18.05M$19.25M
Surprise %------------1.09%0.42%2.03%0.61%0.86%1.42%0.86%1.16%0.03%0.71%0.85%0.63%0.76%0.81%0.65%0.38%0.55%0.45%

Autolus Therapeutics's average Quarter SG&A projection for Mar 24 is $12.73M, based on 1 Wall Street analysts, with a range of $10.19M to $15.28M. The forecast indicates a -19.03% fall compared to AUTL last annual SG&A of $15.73M (Dec 23).

Autolus Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts11111111131131111111119151016811711
EPS------------$-0.44$-0.26$-0.26$-0.23$-0.30$-0.47$-0.46$-0.41$-0.57$-0.47$-0.47$-0.53$-0.69$-0.72$-0.62$-0.60$-0.82$-0.61
Avg Forecast$-0.12$-0.14$-0.18$-0.18$-0.19$-0.21$-0.22$-0.22$-0.20$-0.21$-0.19$-0.08$-0.25$-0.25$-0.22$-0.27$-0.27$-0.47$-0.42$-0.49$-0.39$-0.51$-0.50$-0.60$-0.77$-0.71$-0.71$-0.74$-0.74$-0.86
High Forecast$-0.12$-0.14$-0.18$-0.18$-0.19$-0.21$-0.22$-0.22$-0.20$-0.19$-0.19$-0.08$-0.22$-0.25$-0.22$-0.27$-0.27$-0.47$-0.42$-0.49$-0.39$-0.51$-0.50$-0.60$-0.77$-0.71$-0.71$-0.74$-0.74$-0.86
Low Forecast$-0.12$-0.14$-0.18$-0.18$-0.19$-0.21$-0.22$-0.22$-0.20$-0.22$-0.19$-0.08$-0.28$-0.25$-0.22$-0.27$-0.27$-0.47$-0.42$-0.49$-0.39$-0.51$-0.50$-0.60$-0.77$-0.71$-0.71$-0.74$-0.74$-0.86
Surprise %------------1.74%1.04%1.16%0.86%1.12%1.00%1.10%0.83%1.48%0.93%0.94%0.88%0.90%1.02%0.87%0.81%1.11%0.71%

According to undefined Wall Street analysts, Autolus Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AUTL previous annual EPS of $NaN (undefined).

Autolus Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
XFORX4 Pharmaceuticals$0.53$3.67592.45%Buy
INZYInozyme Pharma$4.42$14.67231.90%Buy
ANEBAnebulo Pharmaceuticals$1.89$6.00217.46%Buy
AUTLAutolus Therapeutics$3.34$9.50184.43%Buy
APLSApellis Pharmaceuticals$28.56$76.13166.56%Buy
DAWNDay One Biopharmaceuticals$14.81$38.80161.99%Buy
RZLTRezolute$5.44$13.50148.16%Buy
ABOSAcumen Pharmaceuticals$2.95$7.00137.29%Buy
CELCCelcuity$15.36$31.50105.08%Buy
TERNTerns Pharmaceuticals$7.10$14.25100.70%Buy
CGEMCullinan Oncology$15.92$31.5097.86%Buy
LYRALyra Therapeutics$0.26$0.5092.31%Hold
BOLTBolt Biotherapeutics$0.67$1.0049.25%Hold
VECTVectivBio$16.87$18.006.70%Buy
AMLXAmylyx Pharmaceuticals$5.70$5.33-6.49%Buy
IKNAIkena Oncology$1.72$1.33-22.67%Buy

AUTL Forecast FAQ


Yes, according to 3 Wall Street analysts, Autolus Therapeutics (AUTL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of AUTL's total ratings.

Autolus Therapeutics (AUTL) average price target is $9.5 with a range of $8 to $11, implying a 184.43% from its last price of $3.34. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for AUTL stock, the company can go up by 184.43% (from the last price of $3.34 to the average price target of $9.5), up by 229.34% based on the highest stock price target, and up by 139.52% based on the lowest stock price target.

AUTL's average twelve months analyst stock price target of $9.5 supports the claim that Autolus Therapeutics can reach $5 in the near future.

Autolus Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $59.38M (high $59.38M, low $59.38M), average EBITDA is $-59.38M (high $-59.38M, low $-59.38M), average net income is $-224M (high $-224M, low $-224M), average SG&A $2.38B (high $2.38B, low $2.38B), and average EPS is $-0.84 (high $-0.84, low $-0.84). AUTL's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $128.33M (high $128.33M, low $128.33M), average EBITDA is $-128M (high $-128M, low $-128M), average net income is $-165M (high $-165M, low $-165M), average SG&A $5.15B (high $5.15B, low $5.15B), and average EPS is $-0.619 (high $-0.619, low $-0.619).

Based on Autolus Therapeutics's last annual report (Dec 2023), the company's revenue was $1.7M, beating the average analysts forecast of $1.5M by 13.28%. Apple's EBITDA was $-176M, beating the average prediction of $-57.402M by 205.79%. The company's net income was $-208M, missing the average estimation of $-247M by -15.57%. Apple's SG&A was $46.74M, missing the average forecast of $60.13M by -22.26%. Lastly, the company's EPS was $-1.2, beating the average prediction of $-0.993 by 20.82%. In terms of the last quarterly report (Sep 2023), Autolus Therapeutics's revenue was $406K, missing the average analysts' forecast of $624.8K by -35.02%. The company's EBITDA was $-44.014M, beating the average prediction of $-625K by 6944.49%. Autolus Therapeutics's net income was $-45.849M, missing the average estimation of $-66.384M by -30.93%. The company's SG&A was $10.61M, missing the average forecast of $25.06M by -57.66%. Lastly, the company's EPS was $-0.26, beating the average prediction of $-0.25 by 4.19%